New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease Â
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…